deep dive analyz potenti continu outperform
around structur growth companion anim ca outlook simparica
trio diagnost strateg fit debat right multipl pay
game plan around diagnost key drive lt growth ca vet
diagnost sector grew recent acquisit znlab
phoenix underlin strateg import conclud may seek
creat larg diagnost setup like refer lab help strengthen
relat critic vet channel vet ca channel cement
lt ca growth forecast compound-annual-growth-rate vs compound-annual-growth-rate earlier
simparica trio like first pet drug franchis dive us eu market
trio launch like analyz driver first-mov advantag
current futur competit landscap look benign potenti share gain
market expans us rise compliance/dur ex-u potenti eu
canada market reson prefer global exposur forecast
simparica franchis overtak apoquel cornerston ca
lt growth theme explor note livestock trend asf pipelin
believ african swine fever continu prevail impact
play recoveri cattl structur demand ca continu
driven evolv diseas trend innov futur launch especi biolog
flag best-ev pipelin increas access multipl channel
valuat debat right multipl strong stock current trade
consensu earn vs histor rang target pe
base premium vs histor mean reflect ztss leadership sustain high
roci profil ep compound-annual-growth-rate sustain scarciti premium investor
seek defens growth rais pt base new
estim impli potenti return recent report
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
idc link barclay live interact chart
overweight ow driven
new launch companion anim health
greater thrust toward biolog drug
unmet need chronic diseas pet also
expect continu effici alloc
capit done past value-ad
strong global growth faster anticip margin
expans earlier launch symparica trio valu
weak integr abaxi delay launch
symparica trio greater anticip competit
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
strateg import build refer lab
network us/glob vet diagnost market
diagnost strategi long-term focu interest strengthen ca
us veterinari diagnost market size grown annual rate
past year one fastest growth area anim
health industri phoenix znlab acquisit reiter interest
continu bolt-on acquisit refer lab well build intern manag
expect refer lab ex-abaxi ep dilut build hub
spoke model invest nation scale refer lab tend focus local
market strong emphasi rout highlight identifi diagnost
space opportun earn call
thought around recent acquisit phoenix znlab lt bundl opportun
complet acquisit phoenix lab octob znlab novemb
refer lab purchas undisclos term estim
drove annual revenu like deal valu compar around
manag describ buy build strategi hub spoke model
phoenix west coast hub znlab east coast hub plan build
spoke scale highli popul area adjac major center
connect advantag bring describ hub locat louisvil ky
strateg interest along znlab got spoke laboratori bois chicago
believ also yield long term bundl advantag discuss
note strateg import strengthen relat vet convers
manag also reveal geograph exposur region competit strength
strong factor futur inorgan focu
updat abaxi integr intern expans potenti longer term
may zoeti enhanc diagnost portfolio acquisit abaxi
abaxi suppli point-of-car blood analyz medic veterinari market
abaxi recent launch vetscan test detect heartworm lyme ehrlichia
anaplasma diseas dog well vetscan canin pancreat lipas rapid test
vetscan portfolio includ benchtop handheld diagnost instrument
wit serelisa proflok line immunodiagnost kit provid diseas
detect capabl dog cat cattl pig poultri
regard progress integr abaxi consid foundat year
build stabl field forc base manag see materi opportun intern
expect time diagnost segment compar ebit margin
rest busi manag highlight consid diagnost busi
import part veterinarian practic opportun provid better
overal experi custom
estim vet current drive petcar channel revenu refer lab
help strengthen strategi focus vet
overview global diagnost market opportun
estim current diagnost space approxim revenu
domin grew compound-annual-growth-rate smaller market
particip includ antech acquir mar septemb abaxi acquir
juli well larg number small independ lab calcul
lower cagr abax well assum compound-annual-growth-rate
independ oper review main market player
cover headquart main largest player
diagnost market focus refer laboratori test diagnost imag
softwar also suit in-hous analys also build
refer laboratori network novemb acquisit marshfield
laboratori revenu estim
mar petcar privat enter diagnost market septemb
acquisit vca includ anim hospit antech
diagnost lab acquir vca laboratori busi
estim mar compris current diagnost space
cover base colorado focus in-hous lab
diagnost element product seri well digit imag
cuattro product revenu estim
zoeti enter diagnost space acquisit abaxi
close juli made smaller refer lab acquisit
phoenix znlab reiter interest continu bolt-on
acquisit space abaxi revenu estim
diagnost market space
independ lab market model assum approxim
independ lab us per state gener revenu
drive diagnost market
estim drove half diagnost market revenu
simparica simparica trio like franchis
global market led us eu market grow
global canin parasiticid market size market larg base
develop economi us europ canada discuss
breakdown market reveal market domin
ectoparasit market flea tick endoparasiticid market make rest
size geograph us market constitut major size
ex-u market size
import constitu invest framework balanc global exposur
theme underpin prefer believ market continu
grow advanc like trio spectra also abil compani
like zoeti introduc drug newer market like china latin america
current compar scale develop market review current
underway brazil submiss japan china australia
chewabl tablet consist
sarolan drug isoxazolin class flea tick
moxidectin heartworm intestin worm
monthli dosag approv tablet strength eu expect similar
approv us market
combat ecto flea tick endo parasit heartworm
give zoeti vastli differenti product domin us market thu
global canin parasiticid market current
simparica trio first parasiticid us target flea tick worm
driver trio market potenti
expand complianc also broader market mani pet
owner current use
tick
roundworm/hookworm medic amongst current user durat
therapi also vari mani user use product month even shift
usag behaviour month month trio vs like label
recommend around year use signific impact market size
maxim first market advantag us current bi nexgard
spectra approv europ trio compet
howev us market nexgard spectra expect next year
give trio signific first mover advantag build brand drive consum
convers ensur sticki pet owner adapt trio
puppi indic week month estim dog
popul us plu vet trio highlight trial
design achiev indic puppi follow surpris
receiv simparica seen strong excit vet
decreas number sku hand tripl combin product
larg advantag competit big box retail current estim
around puppi annual pet owner give
medic puppi indic potenti expand
estim total number pet us type anim
parasiticid competit landscap trio
wide rang parasiticid key competit trio
approv drug isoxazolin class drug merck bravecto fluralan tablet
topic solut dog merial/bi nexgard afoxalan tablet dog elan credelio
lotilan tablet dog revolut selamectin sarolan topic
solut cat
nexgard spectra beef-flavour chew provid protect flea tick
heartworm prevent control intestin infest dog puppi
nexgard nexgard spectra revenu achiev
growth vs key take-away zoeti though signific
potenti combin parasiticid market factor key market model similar
trio nexgard spectra recommend administ year around
larg part trio revenu like come cost competit refer market
model uniqu tripl combin product nexgard spectra yet launch
usd market competitor product like impact nexgard bravecto
discuss cannib simparica addit trio also like
take market away topic solut mention includ bravecto
credelio over-the-counter product
type petpopul barclay zoeti inc
market model assumpt underli trio forecast
estim revenu simparica trio driven estim net
therapi cost assum premium price current product option
month disclos thought around price yet expect trio
launch premium deter pet owner still attract enough price
convert exist user simparica compet product believ premium
simparica could achiev result
estim simparica trio drive peak unadjust global revenu
extent simparica cannib beyond
current per estim expect simparica end around
revenu declin believ signific part market
introduc simparica last year like move trio consid
advantag combat addit parasit beyond factor simparica
declin path pace declin influenc quantum premium trio
may command simparica current model simparica constitut small
proport simparica franchis declin
canin ecto endo parasit market
biolog vector vaccin growth driver beyond trio
ztss biolog program expect focu pain inflamm cancer cat
dog diseas trend continu evolv longev pet increas
regeneron licens veloclmmun antibodi technolog modifi
companion livestock anim use regeneron receiv licens fee approv
sale mileston payment royalti potenti veterinari treatment
velocimmun produc fulli human mab allow tightli bind therapeut
target avoid potenti immun respons may occur patient receiv
antibodi contain nonhuman typic mous compon
expect launch felin mab europ us canin mab
follow thereaft see limit competit mab anim health firm
amongst coverag compar breadth biolog pipelin
mention past believ partnership potenti futur
biolog partnership highlight follow drug regeneron pipelin
potenti move anim studi futur develop
product regeneron mab pipelin
vector vaccin poultri first vaccin launch novemb
zoeti also flag vector vaccin new antibiot class poultri key growth
driver longer term compani recent announc launch approv
first vector vaccin poulvac procerta hvt-nd protect contagi viral
diseas like marek diseas newcastl diseas futur commerci thrust
build broader portfolio vaccin address multipl diseas evolv
combin product current factor explicitli near-term
livestock overview poultri beef aquacultur swine
cattl continu drive half livestock revenu swine poultri
segment contribut estim
livestock revenu speci
cattl mt lt growth intact em driver recoveri dairi
recent breakfast meet manag repli question longer term
growth outlook intact state demand ex-u market led em
latam apac continu drive livestock growth potenti challeng
altern meat sourc impact space sourc adjac
impact meat demand dairi side start see pressur
dairi market eas usda data show price milk gallon y/i
expect cattl segment return modest growth revert industri
mean growth beyond
cattl expect revenu compound-annual-growth-rate
swine set return growth asf play rais revenu forecast
increas pork product take time grow new herd brazil eu often
identifi area could increas product fill gap china ztss expect
asf impact flatten expect re-herd gradual process due
natur increas livestock product expect growth region
partial off-set asf pressur swine segment return posit growth
swine expect revenu compound-annual-growth-rate
poultri sustain growth driven anti-coccidi market dynam
expect poultri one larger offset asf pressur given faster natur
grow chicken open poultri export china expect poultri
grow line anim health market near futur
poultri expect revenu compound-annual-growth-rate
aquacultur fastest-grow protein segment demand evolv
manag recent highlight aquacultur fastest grow speci view
expans industri fish particularli tilapia pangasiu larg
opportun expect short-term choppi space long-term mostli
organ vision expand pipelin capit high aquacultur demand
increas fish segment estim expect compound-annual-growth-rate
fish expect revenu compound-annual-growth-rate
improv product mix effici drive opm rise
new ceo kristin peck succe juan ramon alaix reiter
continu futur focu margin top signific margin expans past
sever year estim consid modest increas
sourc futur margin expans
improv product mix higher valu product gain traction newer product
like trio launch higher price point simparica trio alon materi
impact lt margin profil
recoveri livestock busi
longer term dilut effect trio launch refer lab integr
play
gross margin expans geographi
expect high-margin ah product rais qualiti revenu
total gm ebitda margin expect expans
simparica suit margin key driver group opm
margingross barclay zoeti inc
valuat debat focus right multipl pay
rais pt base new simparica trio diagnost
livestock estim use pe multipl prior valu higher end
histor trade rang stabl defens growth expect multipl
stay intact compani continu deliv strong revenu earn growth
incom call investor focu pe multipl zoeti abil
valuat sustain level right view earn deceler
like accompani multipl compress level howev
revisit earn stabil fundament anim health industri
continu make case multipl sustain level zoeti continu
deliv doubl digit earn growth current forecast ep compound-annual-growth-rate
ebitda compound-annual-growth-rate
deriv addit support industri lead cash return profil
view set improv continu pursu effici capit alloc
strategi recent dividend hike demonstr capit alloc goal focu
gener return sharehold current factor share buyback
model septemb approxim remain
share repurchas author firm also ampl firepow leverag ratio
downsid risk thesi includ
slower expect simparica trio
fx headwind usd strength
asf impact continu play
ntm price earn price-to-earnings ratio
pt base pe multipl
 dog bring bacon ow barclay equiti research
nt lt growth driver intact breakfast meet new ceo barclay equiti
pe multiplehistor average multipl base per share barclay zoeti inc
balaji prasad md herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
